Eyas Medical Imaging Receives 510(k) Clearance for Ascentᵀ Ultrasound Device
Eyas Medical Imaging has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Ascentᵀ ultrasound device, a meaningful milestone for the company. This clearance enables healthcare professionals to utilize the device’s advanced imaging capabilities to improve outcomes for critically ill newborns.Eyas Medical Imaging announced the clearance on january 30, 2024.
What is the Ascentᵀ Ultrasound Device?
The Ascentᵀ is a point-of-care ultrasound device designed for neonatal and pediatric intensive care units. It provides high-resolution imaging to aid in the diagnosis and treatment of a range of conditions in newborns, including intraventricular hemorrhage, pneumothorax, and congenital heart defects. The device’s portability and ease of use allow for rapid assessment at the bedside, possibly leading to faster interventions and improved patient care.
Importance of 510(k) Clearance
510(k) clearance is a pathway for medical device manufacturers to demonstrate that their device is substantially equivalent to a legally marketed predicate device. This means the FDA has resolute that Ascentᵀ is as safe and effective as existing, similar devices. According to the FDA, moast Class II medical devices are cleared through the 510(k) process.
“510(k) clearance marks a significant milestone for the company and reflects our mission to enable healthcare professionals to save more babies’ lives with state-of-the-art, precision imaging,” said nr, as stated in the company’s press release.
Commercialization and Availability
Eyas Medical Imaging is scaling up operations and plans to commercialize Ascentᵀ in the US later in 2024. As of February 7, 2026, the device is not yet commercially available in other countries. The company is focused on establishing a strong presence in the US market before expanding internationally.
Key Takeaways
- Eyas Medical Imaging’s Ascentᵀ ultrasound device has received 510(k) clearance from the FDA.
- The device is designed for use in neonatal and pediatric intensive care units.
- Ascentᵀ provides high-resolution imaging for rapid diagnosis and treatment of newborn conditions.
- Commercialization in the US is planned for later in 2024, with international expansion to follow.
Keep reading